The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials.
OBJECTIVE
To determine whether the use of luteal phase support improves pregnancy rate (PR) in infertility.


METHODS
A meta-analysis of randomized trials of luteal phase support. Search of the National Library of Medicine MEDLINE data base from 1971 using the words luteal, pregnancy, human, and comparative. Bibliography of relevant articles, reviews, and abstracts of scientific meetings were hand searched. All randomized controlled trials of luteal phase support in infertility were included. Luteal phase support for recurrent abortion and nonrandomized trials were excluded. The common odds ratio was calculated for each intervention using the Mantel-Haentzel test. Homogeneity of treatment effect was evaluated using the Breslow-Day test.


METHODS
Pregnancy per cycle, rate of spontaneous abortion, and ovarian hyperstimulation syndrome rate.


RESULTS
Eighteen trials met the above criteria. Human chorionic gonadotropin improved PRs in IVF when GnRH agonist (GnRH-a) was used (n = 151) and was superior to P (n = 352). Its benefit in all IVF cycles, however, was not established because of significant heterogeneity of treatment effect. Progesterone improved the PR in all IVF cycles (n = 457). No significant reduction in spontaneous abortion was noted with luteal support (n = 200). Ovarian hyperstimulation syndrome occurred in 5% of patients with hCG. Combination of data from trials of luteal support with other infertility therapies was not possible because of the differences in patient populations.


CONCLUSIONS
The meta-analysis supports the routine use of hCG in IVF cycles using a GnRH-a. Progesterone was also beneficial for luteal phase support in IVF. For other infertility therapy, however, further research is needed to evaluate the role of luteal phase support.
Soliman
S
S
Department of Obstetrics and Gynaecology, McMaster University, Hamilton, Ontario, Canada.
Daya
S
S
Collins
J
J
Hughes
E G
EG
D000022:Abortion, Spontaneous / Q000453:epidemiology; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D015994:Incidence; D007247:Infertility, Female / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*; D008183:Luteal Phase / Q000502:physiology*; D016471:Ovarian Hyperstimulation Syndrome / Q000453:epidemiology; D011247:Pregnancy; D011374:Progesterone / Q000627:therapeutic use; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic
D006063:Chorionic Gonadotropin; D011374:Progesterone